Focused update: Guidelines of care for the management of atopic dermatitis in adults - 19/08/25
, Ali Alikhan, MD c, Lionel Bercovitch, MD d, David E. Cohen, MD, MPH e, Jennifer M. Darr, LCSW f, Aaron M. Drucker, MD, ScM g, h, Lawrence F. Eichenfield, MD i, Amy S. Paller, MD j, Kathryn Schwarzenberger, MD k, Jonathan I. Silverberg, MD, PhD, MPH l, Anne Marie Singh, MD m, Peggy A. Wu, MD, MPH n, Robert Sidbury, MD, MPH (Co-Chair) oAbstract |
Background |
In 2023 and 2024, the American Academy of Dermatology published guidelines on the use of topical and systemic therapies for the management of atopic dermatitis (AD) in adults. Since the publication of these guidelines, several novel therapies have emerged to treat AD.
Objective |
To update previous guidelines on the management of AD in adults by providing evidence-based recommendations on the use of additional Food and Drug Administration–approved topical and systemic therapies.
Methods |
A multidisciplinary workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations.
Results |
The workgroup developed 4 new recommendations for the management of AD in adults.
Limitations |
This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of the considered therapies for AD are of short duration, limiting comparative long-term efficacy and safety conclusions.
Conclusions |
The workgroup developed strong recommendations for the use of tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab with concomitant topical therapy.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, biologic, eczema, lebrikizumab, nemolizumab, roflumilast, tapinarof, topical agents
Abbreviations used : AAD, AD, DLQI, EASI-75, FDA, IGA, POEM, TCI, TCS
Plan
| Funding sources: This study was funded in total by internal funds from the American Academy of Dermatology. |
|
| Prior presentation: Contents have not been previously presented. |
|
| Disclaimer: Adherence to these guidelines will not ensure successful treatment in every situation. Furthermore, these guidelines should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care, nor exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient, and the known variability and biologic behavior of the disease. This guideline reflects the best available data at the time the guideline was prepared. The results of future studies may require revisions to the recommendations in this guideline to reflect new data. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
Vol 93 - N° 3
P. 745.e1-745.e7 - septembre 2025 Retour au numéro
Article précédent
- Genitourinary syndrome of menopause: An important diagnosis for dermatologists
- Menopause and Women's Health in Dermatology Quality Improvement Workgroup, Alice Watson, Keira Barr, Neelam Vashi, Abigail Cline, Beth N. McLellan, Mona El-Shamma, Shoshana Marmon
- Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current and emerging therapies
- Michael M. Ong, Marc Avram, Amy McMichael, Antonella Tosti, Shari R. Lipner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?